Skip to main content

Table 1 Patient information

From: Safety and efficacy analysis of chemoradiotherapy/radiotherapy combined with nimotuzumab for treating unresectable oesophageal squamous cell carcinoma in elderly patients: a retrospective analysis

Characteristics

Total (n = 54)

NRT group (n = 28)

NCRT group (n = 26)

Gender

   

 Male

42 (77.8%)

22 (78.57%)

20 (76.92%)

 Female

12 (22.2%)

6 (21.43%)

6 (23.08%)

Age

   

 70–79 years old

41 (75.9%)

16 (57.14%)

25 (96.15%)

 More than 80 years old

13 (24.1%)

12 (42.86%)

1 (3.85%)

KPS

   

 70–80

28 (51.9%)

19 (67.86%)

9 (34.62%)

 90–100

26 (48.1%)

9 (32.14%)

17 (65.38%)

Location of the tumor

   

 Upper esophagus

8 (14.8%)

2 (7.14%)

6 (23.08%)

 Middle esophagus

28 (51.9%)

16 (57.14%)

12 (46.15%)

 Lower esophagus

18 (33.3%)

10 (35.72%)

8 (30.77%)

Stage of T

   

 T1

3 (5.6%)

1 (3.57%)

2 (7.69%)

 T2

12 (22.2%)

5 (17.86%)

7 (26.92%)

 T3

22 (40.7%)

14 (50.00%)

8 (30.77%)

 T4

17 (31.5%)

8 (28.57%)

9 (34.62%)

Stage of N

   

 N0

16 (29.6%)

8 (28.57%)

8 (30.77%)

 N1

18 (33.3%)

12 (42.86%)

6 (23.08%)

 N2

19 (35.2%)

8 (28.57%)

11 (42.31%)

 N3

1 (1.9%)

0 (0)

1 (3.84%)

Tumor stage

   

 I

3 (5.5%)

1 (3.57%)

2 (7.70%)

 II

11 (20.4%)

7 (25.00%)

4 (15.38%)

 III

21 (38.9%)

11 (39.29%)

10 (38.46%)

 Iva

19 (35.2%)

9 (32.14%)

10 (38.46%)

Smoking

37 (68.52%)

19 (67.86%)

18 (69.23%)

  1. NRT, nimotuzumab + radiotherapy; NCRT, nimotuzumab + chemo-radiotherapy; KPS, Karnofsky performance status; T, tumor; N, node